of a high-need patient group: people diagnosed with cancer. The Australian system for these services is predominantly … costs for patients in the 12 months following on cancer diagnosis and find a large variation in these costs according to the …

cancer in order to be (re-)integrated at the workplace and/or to regain social inclusion. The different approaches and … awareness of breast cancer patients during the 'breast cancer month October'. …

The likelihood of cancer emergence is highly dependent on the underlying tissue structure. This article gives … cancer. In a second step, a mathematical framework is proposed, within which the risk of cancer emergence can be expressed …

involved. It has been argued that cancer should be considered a "dread disease", which supports the use of a "cancer premium …". The objective of this study is to elicit the existence and size of a cancer premium (for pancreatic cancer and multiple …-76 %) for cancer was found in relation to road traffic accidents, but not in relation to ALS and sudden cardiac arrest. The …

. The objective of this study is to elicit the existence and size of an EoL premium in cancer. Data was collected from 509 …. The value of a QALY at EoL in cancer was between €275,000 and €440,000, which is higher than the thresholds applied by … showed scale sensitivity. Thus this study supports an EoL premium in cancer when expected remaining lifetime is short. …

To study hiring discrimination against cancer survivors, we conduct a vignette experiment in which American and British …-employment due to suffering from cancer. We study the effect of cancer experiences on the recruiters' hiring decisions, as well as …. We find that employment opportunities are lower for candidates with a history of cancer, compared to candidates without …

consequences of health shocks or the mechanisms behind the spillover effects. We analyse the short- and long-term effects of cancer … breadwinner type). We use full population register data on all cancer patients and their cohabiting partners in Finland over the … period 1995-2019. Our identification strategy is based on the quasi-random variation in the timing of the cancer diagnosis …